share_log

萬科企業:董事會召開日期

CHINA VANKE: DATE OF BOARD MEETING

HKEX ·  Oct 21 22:47

Summary by Moomoo AI

萬科企業股份有限公司(「萬科企業」)宣布將於2024年10月30日(星期三)召開董事會會議,主要議程為考慮及批准公司及其附屬公司截至2024年9月30日止的三個月及九個月季度業績,並進行發佈。會議將由公司秘書朱旭先生主持,董事會成員包括執行董事郁亮、祝九勝、王蘊,非執行董事辛傑、胡國斌、黃力平、雷江松,以及獨立非執行董事廖子彬、林明彥、沈向洋博士和張懿宸。此次會議將對萬科企業的短期及中期財務表現進行審核。
萬科企業股份有限公司(「萬科企業」)宣布將於2024年10月30日(星期三)召開董事會會議,主要議程為考慮及批准公司及其附屬公司截至2024年9月30日止的三個月及九個月季度業績,並進行發佈。會議將由公司秘書朱旭先生主持,董事會成員包括執行董事郁亮、祝九勝、王蘊,非執行董事辛傑、胡國斌、黃力平、雷江松,以及獨立非執行董事廖子彬、林明彥、沈向洋博士和張懿宸。此次會議將對萬科企業的短期及中期財務表現進行審核。
China Vanke Corporation ("China Vanke") announced that it will convene a board of directors meeting on Wednesday, October 30, 2024, to consider and approve the quarterly performance of the company and its subsidiaries for the three and nine months ending September 30, 2024, and to make announcements. The meeting will be chaired by the company secretary, Mr. Zhu Xu, and the board members include executive directors Yu Liang, Zhu Jiusheng, Wang Yun, non-executive directors Xin Jie, Hu Guobin, Huang Liping, Lei Jiangsong, as well as independent non-executive directors Liao Zibin, Lin Mingyan, Dr. Shen Xiangyang, and Zhang Yichen. This meeting will review the short-term and medium-term financial performance of China Vanke.
China Vanke Corporation ("China Vanke") announced that it will convene a board of directors meeting on Wednesday, October 30, 2024, to consider and approve the quarterly performance of the company and its subsidiaries for the three and nine months ending September 30, 2024, and to make announcements. The meeting will be chaired by the company secretary, Mr. Zhu Xu, and the board members include executive directors Yu Liang, Zhu Jiusheng, Wang Yun, non-executive directors Xin Jie, Hu Guobin, Huang Liping, Lei Jiangsong, as well as independent non-executive directors Liao Zibin, Lin Mingyan, Dr. Shen Xiangyang, and Zhang Yichen. This meeting will review the short-term and medium-term financial performance of China Vanke.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more